Disability Related Feature Stories and Live Breaking News

Disability Nexus

Subscribe to Disability Nexus : eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Disability Nexus : homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Top Stories

After almost a week had passed, they upgraded me to "He might make it, but he’ll probably never wake up". After I started to stir slightly the story changed again to "Don’t expect him to be the Dave you knew" (referring to the brain injury). After 5 weeks of total unconsciousness, I started to come around somewhat. Mentally I was soon all there, I just couldn’t move or communicate in any way. When they noticed that I was responding to simple requests like "squeeze my hand if you can hear me" they started trying to explain to me where I was. They didn’t want me to know too much about just how bad I was though, "they thought it would be best." Like I wouldn’t find out? Thankfully my family was there and would explain things to me so I could begin to try to understand where I was & what was happening to me. What a terrifying experience, to be conscious, not knowing where... (more)

Merck Serono et Ono Pharmaceutical établissent des collaborations pour le développement d'un médicament d'administration orale destiné au traitement de la sclérose en plaques et d'un agent d'immunothérapie anticancéreuse

GENEVE, Suisse, October 4, 2011 /PRNewswire/ -- Merck Serono va collaborer avec Ono pour le développement et la commercialisation de ONO-4641, un agent expérimental administré par voie orale, qui module le récepteur à la sphingosine-1-phosphate (S1P), actuellement en Phase II de développement clinique dans la sclérose en plaques Les deux sociétés vont également collaborer au Japon pour le développement et la commercialisation de Stimuvax, un médicament expérimental d'immunothérapie pour le traitement du cancer, actuellement en Phase III de développement clinique Merck Serono, division de Merck KGaA (Darmstadt, Allemagne), a annoncé aujourd'hui avoir signé deux accords distincts avec Ono Pharmaceutical Co., Ltd. (Osaka, Japon) pour renforcer ses activités dans les domaines de la sclérose en plaques et de l'oncologie. Le premier accord octroie à Merck les droits de... (more)

Duchenne Muscular Dystrophy Advocates Take to the Hill

Parent Project Muscular Dystrophy Holds 13th Annual Advocacy Conference WASHINGTON, Feb. 27, 2012 /PRNewswire-USNewswire/ -- Nearly 80 parents, grandparents, and relatives of boys with the most common form of muscular dystrophy will be on Capitol Hill today and tomorrow urging Members of Congress to support critical research and patient care initiatives. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ) Advocates from 23 states are participating in the 13th annual advocacy event sponsored by Parent Project Muscular Dystrophy (PPMD), the largest Duchenne muscular dystrophy advocacy organization in the nation. Thanks in large part to Congress's commitment to Duchenne patient care and research initiatives over the past decade, the average life expectancy has increased by nearly 10 years, and nearly 20 potential therapies are in various stages of cli... (more)

FONAR Reports 12 Straight Quarters of Net Income From Operations and Six Straight Quarters of Profitability Greater Than $1.5 Million in 2nd Quarter Financial Results

MELVILLE, NY -- (Marketwire) -- 02/14/13 -- FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its second quarter financial results of fiscal 2013. In addition to profitability being greater than $1.5 million for six straight quarters, the Company has had twelve straight quarters of income from operations. In spite of Hurricane Sandy reaping havoc in the area that four of its scanning centers are located, revenues for FONAR's imaging management division advanced when compared to a year ago or last quarter. FONAR's business is based upon utilization of its UPRIGHT® Multi-Position™ MRI, also called the STAND-UP® MRI. Statement of Operations Items Income from operations for the six months and quarter ended December 31, 2012, was $3.6 million and $1.7 million, respectively, as compared to $3.7 million and $1.9 million respectively, for the sa... (more)

Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

NEW YORK, NY and GENEVA -- (Marketwire) -- 03/19/13 -- Addex Therapeutics / Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, and The Michael J. Fox Foundation for Parkinson's Research announced today that the Foundation awarded a $1,000,000 grant to Addex to help fund continued human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). One-third of people with PD develop dyskin... (more)

Monteris Medical’s NeuroBlate System Receives 510(k) Clearance

Monteris® Medical announced today that the U.S. FDA has issued a second 510(k) clearance for their MRI-guided ablation device for brain tumors and other lesions. The NeuroBlate® System is a second generation device employing a surgical laser to ablate (lethally heat) diseased brain tissue with updated visualization provided by active MRI. A first generation system has been available in US hospitals since 2010. Dr. Gene Barnett, MD, MBA, Burkhardt Chair in Neurosurgical Oncology, Cleveland Clinic Neurological and Cancer Institutes offered, “The NeuroBlate System will make laser ablation of brain lesions accessible to more neurosurgeons by virtue of its intuitive user interface and time-saving enhancements. Cleveland Clinic will soon be employing this tool to treat brain tumor patients who are seeking a minimally invasive option or are not candidates for traditional ... (more)

StemGenex® Announces Patient Satisfaction Ratings for Stem Cell Centers

LA JOLLA, Calif., Dec. 17, 2013 /PRNewswire/ -- StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the public release of their satisfaction ratings for patients who have received stem cell therapy through StemGenex.  Patients have trusted StemGenex for years to provide them with access to cutting edge stem cell therapies at the absolute highest levels of care.  StemGenex believes this is something that has been lacking in the industry for some time now.  These ratings now allow the public transparency into patient satisfaction in multiple categories which are now posted and updated monthly on the StemGenex website.  StemGenex works tirelessly to provide the absolute highest level of care for patients and is very proud of the overwhelmingly positive... (more)

Inergetics Appoints Dr. Michelle Sexton as Member of Scientific/Medical Advisory Board for Development of CBD-Based Nutritional Supplements

NEWARK, N.J., March 19, 2014 /PRNewswire/ -- Inergetics, Inc. (OTCBB: NRTI), a leading developer of nutritional supplements, today announced the appointment of Dr. Michelle Sexton to its Scientific/Medical Advisory Board for guiding the formulation of the proprietary line of cannabidiol (CBD)-based nutritional supplements it is developing in partnership with Terra Tech Corp (OTCBB: TRTC).  The two companies announced the formation of the Scientific/Medical Advisory Board on March 5, 2014. Dr. Sexton is a highly-respected expert in the medicinal applications of cannabis, naturopathic medicine and the phytochemistry of plant medicine, with more than 15 years of experience in natural, herbal and holistic medicine.  She currently serves as the Executive Medical Research Director at the Center for the Study of Cannabis and Social Policy in Seattle.  For the past several... (more)

Filament Labs Raises $1 Million to Transform Mobile Health Care With Patient IO, A Care Plan Platform For Health Professionals

Filament Labs raised $1 million in a seed round led by Mercury Fund to grow their flagship product, Patient IO, a care plan delivery platform for health professionals. Patient IO helps health professionals create personalized care plans that can be seamlessly delivered to patients outside the clinic. The platform’s mobile care plans enable patient self-care and unlock superior data insights about adherence and patient health outside the clinic. Learn more about Patient IO at http://patientio.com. For patients, Patient IO enables doctors to deliver treatment-specific tasks, reminders and educational content directly to patients’ or their caregivers’ smartphones. Patient IO synthesizes multiple care plans from multiple providers into a unified set of daily tasks for the patient. Health professionals can review submitted health information in real-time as patients com... (more)

MSBoston2014 Kicks Off The Largest MS Gathering In History On September 11th With Overarching Look At MS Landscape And Gripping Video From The Sailing Sclerosis Foundation Oceans Of Hope Crew's First Transatlantic Crossing

-- Crew of Sailors with MS including Bostonian Demonstrate Ability to Overcome Personal Challenges~ -- Dr. David Hafler Presents the Cause of MS and the Impact of Environmental Stimuli Interacting with Genetic Factors on the Disease~ BOSTON, Sept. 4, 2014 /PRNewswire/ -- On Thursday, September 11th at 8:30 a.m., MSBoston2014 -- the world's largest international conference exclusively devoted to research in multiple sclerosis (MS) -- will host its opening ceremony with Dr. Dhib-Jalbut, President of ACTRIMS, providing an overarching look at the MS landscape. In his address, he will underscore the critical importance of MS research, the developments and breakthroughs that have been realized, and the difference these advances have made in the lives of those living with MS, as well as those caring for them. He will also speak of the challenges that lie ahead and new area... (more)

Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the Treatment of Haemophilia A

DIEPENBEEK, Belgium, November 25, 2014 /PRNewswire/ -- Treatment for haemophilia A patients developing Factor VIII inhibitors   Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the blood in response to any type of injury or surgery. It is a genetic disorder that causes missing or defective Factor VIII, an essential blood-clotting protein. Haemophilia A patients are normally treated with Factor VIII to help with the clotting of their blood. However, since these patients' immune systems hav... (more)